Ticker	Current Price	Change	Graph
IBB	119.96	1.41 (1.19%)
XBI	96.62	1.08 (1.13%)

Restructuring

Chopping close to home, Novartis outlines plans to ax or move about 2,600 more jobs in another wave of global restructuring

New Products

Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success

Venture

Praveen Tipirneni's team at Morphic reels in an $80M round as they turn into the last stretch to the clinic — and a deal

Latest

NEWResearchers point to R&D treaty to spur new infectious disease treatments →

AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that's important →

Cash-strapped Gemphire lets go of five staffers as it contends with a clinical hold →

An autoimmune upstart turns PD-L1 around to blaze a new approach to diabetes, multiple sclerosis →

AstraZeneca CEO Pascal Soriot: 'I'm the lowest-paid CEO in the whole industry' →

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial →

Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M →

PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO →

FDA gives Epizyme a green light on trial recruitment, but tazemetostat isn’t completely out of the woods yet →

Top News

UPDATED: Amarin scores a big win for its cardio outcomes study on Vascepa — stock races higher as analysts applaud

John Carroll

Parker collaborator Tessa allies with St. Jude, launches a new T cell program for pediatric brain cancer

John Carroll

Novartis drums up EU launch plans as CHMP gives thumbs up to Spark's gene therapy Luxturna

Amber Tong

Giant Amgen joins a nascent effort to build a new biotech hub in LA

John Carroll

European regulators are locking the door on Sarepta’s Duchenne drug — but they aren’t throwing away the key

John Carroll

More news

Protocols

Quick hits from around the biopharma web

Sep 24

Chinese biotech investors are pouring billions into US companies; Nektar partners with BioXcel on new I/O triple

Sep 21

Bayer wins OK for hemophilia A treatment; Agenus sells off a slice of future royalties for $15M

Sep 20

Brian Gallagher jumps from SR One to running the Boston office for Abingworth; Portola goes with commercial vet for new CEO

Sep 19

UK advises against covering Novartis' Kymriah for adults; Ex-Mast chief Brian Culley appointed CEO at BioTime

More Protocols

Premium

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

Top 10 pipeline blowups, setbacks and snafus in H1 2018

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

Marco

Hot BioTwitter bot - last updated ago

Most Viral

TG Therapeutics credibility vanishes with blood cancer drug trial setback - STAT

STAT a day

Novartis to cut 2,200 jobs in Switzerland to boost profitability

Reuters Reuters Editorial a day

We Offered a Path to Lower Drug Prices And Gilead Listened

Express Scripts a day

Cerecor to Acquire Ichorion Therapeutics - NASDAQ.com

NASDAQ a day

Verastem's duvelisib given go-ahead as Copiktra for CLL/SLL and FL

BioWorld a day

Somatic hypermutation of T cell receptor α chain contributes to selection in nurse shark thymus

eLife a day

TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial

GlobeNewswire News Room TG Therapeutics, Inc. a day

Amarin claims a big win for its cardio outcomes study on Vascepa - and you can bet that makes some people very unhappy

ENDPOINTS NEWS John Carroll a day

Malaria mosquitoes wiped out in lab trials of gene drive technique

Reuters Kate Kelland a day

Novel Drug Approvals for 2018

FDA a day

Latest

Reuters

WHO extremely concerned about Ebola 'perfect storm' in Congo

Evaluate.com

Ionis and Akcea reveal fall-back position

U.K.

Novartis to cut 2,200 jobs in Switzerland to boost profitability

STAT

TG Therapeutics credibility vanishes with blood cancer drug trial setback - STAT

NASDAQ

Cerecor to Acquire Ichorion Therapeutics - NASDAQ.com

GlobeNewswire News Room

Cerecor to Acquire Ichorion Therapeutics

GlobeNewswire News Room

TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial

FDA

Novel Drug Approvals for 2018

FDA Law Blog

FDA Issues Final Rule on Voluntary Malfunction Summary Reporting Program for Device Manufacturers

Evaluate.com

World Lung 2018 - Roche's chemo combo comes up short

Hot This Week

1

STAT

AbbVie accused of paying kickbacks, using a stealthy network to promote Humira

2

STAT

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

3

New York Times

Tiny Device Is a 'Huge Advance' for Treatment of Severe Heart Failure

4

Forbes

Why Former Novartis CEO Joe Jimenez Joined A Microbiome Startup's Board

5

Forbes

At Joe Biden's Urging, Airbnb, WeWork, And Others Commit To Help Cancer Patients

6

JAMA

JAMA Network Retracts 6 Articles That Included Dr. Brian Wansink as Author

7

LifeSciVC

The Incredible Expanding Universe of Biotech Stocks | LifeSciVC

8

ProPublica

Black Patients Miss Out On Promising Cancer Drugs - ProPublica

9

STAT

Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders - STAT

10

The Huffington Post

Chopping close to home, Novartis outlines plans to ax or move about 2,600 more jobs in another wave of global restructuring

Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success

Praveen Tipirneni's team at Morphic reels in an $80M round as they turn into the last stretch to the clinic — and a deal

Latest

NEWResearchers point to R&D treaty to spur new infectious disease treatments →

AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that's important →

Cash-strapped Gemphire lets go of five staffers as it contends with a clinical hold →

An autoimmune upstart turns PD-L1 around to blaze a new approach to diabetes, multiple sclerosis →

AstraZeneca CEO Pascal Soriot: 'I'm the lowest-paid CEO in the whole industry' →

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial →

Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M →

PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO →

FDA gives Epizyme a green light on trial recruitment, but tazemetostat isn’t completely out of the woods yet →

Top News

Protocols

Premium

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

Top 10 pipeline blowups, setbacks and snafus in H1 2018

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password